Nuwellis Expands Aquadex SmartFlow System Capabilities
Nuwellis, Inc. announced strategic development initiatives to expand the capabilities of its Aquadex SmartFlow® System. The program aims to evolve the system into a broader extracorporeal therapy platform by enhancing operating parameters to support higher blood flow rates, expanded pressure ranges, and broader compatibility with advanced therapies. This initiative is intended to expand the company's addressable market beyond fluid overload into critical care applications such as blood purification, immunomodulation, and extracorporeal life support, also enabling future strategic collaborations. These expanded applications are currently research-stage and not yet FDA approved or commercially available.
Key Highlights
- Nuwellis announced strategic development initiatives for its Aquadex SmartFlow® System.
- Aims to expand system capabilities into a broader extracorporeal therapy platform.
- Intends to support higher blood flow rates and expanded operating pressure ranges.
- Will broaden compatibility with advanced extracorporeal therapies beyond ultrafiltration.
- Expands long-term addressable market into critical care applications like blood purification.
- Includes immunomodulation and extracorporeal life support applications.
- Anticipates enabling strategic collaborations with other therapy developers.
- These are research-stage applications, not yet FDA approved or commercially available.
Price Impact
More from NUWE